Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Anthropic IPO Marketing Expected to Start in Mid-October 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Add as a preferred source on Google
CANTON, Mass., Feb. 26, 2018 -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, March 7, 2018 at 4:30 p.m. Eastern Time. The Company will discuss its financial results and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 764-8078. An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its proprietary DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx technology platform is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza ER
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Contact:
Alex Dasalla
[email protected]
